U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. JIVI
  1. Vaccines, Blood & Biologics

STN: BL 125661
Proper Name: Antihemophilic Factor (Recombinant), PEGylated-aucl
Tradename: JIVI
Manufacturer: Bayer Healthcare, Inc 

Indication: 

  • Indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:
    • On-demand treatment and control of bleeding episodes
    • Perioperative management of bleeding
    • Routine prophylaxis to reduce the frequency of bleeding episodes

Product Information

Supporting Documents

Back to Top